IMPRINT
Pantarhei Oncology BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheioncology.nl
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Oncology and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2023
5th Congress of the European Society of Gynecology (November 29, 2023 – December 2, 2023) Amsterdam, the Netherlands
/in NewsWe look forward to attending the upcoming ESG congress in Amsterdam from November 29 to December 2, 2023.
Our CEO, Prof. Herjan Coelingh Bennink will present two lectures:
31st World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI), November 23-25, 2023, Vienna, Austria
/in NewsOn Saturday November 25, 2023, Herjan Coelingh Bennink from Pantarhei will lecture about The history of the fetal estrogen estetrol for human use.
For more information please read the abstract
Interview met Herjan Coelingh Bennink, Olav Andriesse en Nathalie Bries in BiotechNEWS & Life Sciences
/in News, PublicationsPantarhei Bioscience: Eigen. Gedurfd. En uiteindelijk uitermate succesvol.
Pantarhei heeft in haar 23-jarig bestaan mooie stappen gezet. Maar bovenal draait medicijnontwikkeling om geduld en geld. Van allebei liefst veel. Prof. dr. Herjan Coelingh Bennink kan erover mee praten. Maar zijn team en hij geloven onvoorwaardelijk in de toepassingen van Estetrol (E4), ARC (Androgen Restored Contraception) en Zona Pellucida 3 Cancer (ZP3C).
Lees hier het interview met Herjan Coelingh Bennink, Olav Andriesse en Nathalie Bries in BiotechNEWS & Life Sciences.